Which Factors Will Push The Glioblastoma Multiforme Market To Achieve $2.27 Billion By 2029?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Glioblastoma Multiforme Market In The Coming Years?
The market for glioblastoma multiforme has experienced significant growth in recent times. The industry, currently valued at $1.59 billion in 2024, is projected to reach $1.7 billion in 2025, expanding at a compound annual growth rate (CAGR) of 7.3%. The historical growth spurt is credited to the rising cases of glioblastoma multiforme, enhanced healthcare facilities, heightened awareness, better accessibility to innovative treatments, and an expanding elderly population.
In the coming years, the market size for glioblastoma multiforme is anticipated to experience robust growth. The market is projected to reach $2.27 billion in 2029, expanding at a compound annual growth rate (CAGR) of 7.5%. The expected growth during the forecast period can be ascribed to a rise in incidences of cancers related to brain and other parts of the nervous system, wider acceptance of surgical procedures, heightened awareness, timely detection of the disease, and enhancement in the number of R&D undertakings. Key trends to look out for during the forecast period include improvements in healthcare technology, breakthroughs in imaging modalities, personalized treatment approaches, the use of AI in diagnosis, and progressive technological and scientific breakthroughs.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
Which Growth Drivers Are Shaping The Glioblastoma Multiforme Market Outlook?
The glioblastoma multiforme market is likely to be propelled by the increasing instances of brain disorders. Brain disorders, which affect the brain’s structure or function, may result in cognitive, emotional, or physical deficiencies. The surge in these disorders can be attributed to causes like aging populations, longer lifespans, lifestyle elements, and enhanced diagnostic facilities. Research into brain disorders can stimulate advancements in the study of glioblastoma multiforme (GBM), leading to improved early detection methods, novel treatment approaches, and better patient outcomes. Through investigating neurological conditions, researchers can discover genetic and molecular connections that play a part in GBM’s growth. For example, Dementia Australia, a non-profit organization based in Australia, declared in February 2025 that approximately 433,300 Australians are living with dementia. This figure is projected to escalate to 812,500 by 2054. Moreover, in 2025, around 29,000 people are affected by younger-onset dementia, with estimations suggesting a rise to 41,000 by 2054. Consequently, the escalating instances of brain disorders will contribute to the expansion of the glioblastoma multiforme market.
What Is The Segment Breakdown Of The Glioblastoma Multiforme Market?
The glioblastoma multiformemarket covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents; Temozolomide; Carmustine; Lomustine; Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI); Computed Tomography Scan (CT Scan); Biopsy; Other Diagnostic Tools
3) By Treatment Type: Surgery; Radiation Therapy; Chemotherapy; Immunotherapy; Tumor Treating Field Therapy; Other Treatment Types
4) By End-User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents; Platinum-Based Agents; Antimetabolites
2) By Temozolomide: Branded (Temodar); Generic Temozolomide
3) By Carmustine: Injectable Carmustine; Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine); Generic Lomustine
5) By Other Drug Classes: Targeted Therapy; Immunotherapy; Tumor-Treating Fields (TTF) Therapy
How Are Global Trends Impacting The Development Of The Glioblastoma Multiforme Market?
Leading companies in the glioblastoma multiforme market are innovating with cutting-edge treatments like CAR T-cell therapy to address the urgent medical needs of this aggressive cancer. CAR T-cell therapy modifies a patient’s T-cells to effectively identify and destroy cancer cells. For instance, in June 2023, Chimeric Therapeutics Limited, a biotechnology company based in Australia, initiated a Phase IB clinical trial for CHM 1101 (CLXT CAR T) therapy to treat recurrent or progressive glioblastoma multiforme (GBM). The trial, held at several centers, aims to assess the therapy’s safety and efficacy while identifying the optimal Phase 2 dose. Early results from Phase 1a demonstrated disease stability, and the next phase aims to refine development and gather data for regulatory discussions.
Who Are The Major Stakeholders Operating In The Glioblastoma Multiforme Market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
Which Region Is Likely To Register The Fastest Growth In The Glioblastoma Multiforme Market?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21191&type=smp
Browse Through More Reports Similar to the Global Glioblastoma Multiforme Market 2025, By The Business Research Company
Glioblastoma Multiforme Gbm Treatment Global Market Report 2025
Spinal Surgery Devices And Equipment Global Market Report 2025
Cerebrospinal Fluid Management Csf Devices And Equipment Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
